HYPAQUE
LOE ApproachingNDAORAL, RECTALSOLUTION
Approved
Mar 1956
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
HYPAQUE by GE HealthCare is clinical pharmacology retrograde introduction of hypaque-cysto solution provides radiopacity of the contents of the urinary bladder. First approved in 1956.
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYPAQUE is a water-soluble contrast medium (diatrizoate meglumine solution) administered orally or rectally for radiographic imaging of the urinary bladder and lower urinary tract. It provides radiopacity during cystourethrography to detect cystoureteric reflux and evaluate bladder function. The agent remains largely unabsorbed from the urinary tract and is excreted unchanged via renal and hepatic pathways.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), indicating declining market opportunity and likely team consolidation.
Mechanism of Action
CLINICAL PHARMACOLOGY Retrograde introduction of HYPAQUE-CYSTO solution provides radiopacity of the contents of the urinary bladder. When used during micturation as a function test, it also opacifies the bladder neck and lower urinary tract. Continuous fluoroscopic and monitoring of urinary bladder…
Worked on HYPAQUE at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.